27.05.2008 13:00:00
|
Cegedim and Skila Form Alliance to Co-Market Solutions to Life Science Industry
Cegedim and Skila have formed a global alliance to co-market their
products and services to medical and marketing teams in the life
sciences industry.
The co-marketing alliance between Cegedim, a world leader in
pharmaceutical CRM and strategic healthcare industry data, and Skila, a
leader in integrated Marketing and Medical solutions, creates the
industry’s most complete suite of knowledge
and effectiveness solutions for global Medical and Marketing teams.
The global alliance addresses the growing need for pharmaceutical
companies to better understand their clients; streamline their global
teams and business processes; ensure corporate transparency and internal
medical and regulatory compliance; and get the most out of their key
initiatives.
"There is significant customer value in the
partnership between Cegedim and Skila, particularly in the areas of
medical and marketing effectiveness,” says
Laurent Schockmel, CFO of Cegedim Americas. "Our
customers are always looking for innovative end-to-end solutions in
these areas, and this alliance will allow us to provide that.”
The collaboration between Cegedim and Skila will focus on delivering
extensive customer value by helping new and existing customers address
the challenges and opportunities of launching new products and managing
all aspects of thought leader relationships.
"By working together, we offer our clients the
industry’s most unique, robust and sustainable
solutions for identifying and building lasting relationships with
thought leaders, as well as maximizing the effectiveness of global
product launches and the teams responsible for their success”
follows Moish Tov, CEO of Skila.
The Skila solutions that will be co-marketed are:
iAdvocate: Unique technology and continuous services for building and
managing lasting relationships with thought leaders based on the
exchange of actionable knowledge, need and collaboration. Featuring
real-time, dynamic 360-degree key opinion leader profiles; planning ,
targeting, and segmentation tools; meeting preparation and
relationship management tools and services; and medical science
liaison support and effectiveness tracking for each of these
relationships.
iLaunch: Unique technology and continuous services that enables global
launch teams to maximize the effectiveness of their global team by
centralizing knowledge and working as one team.
iPerformance: Unique technology and continuous services that enable
executives to achieve alignment and transparency in managing business
performance across global and local brands and brand portfolios.
The Cegedim solutions that will be co-marketed are:
IcoMed: Measures physicians' preferential attachment to products that
they prescribe while evaluating the size and profile of their
clientele. This personal prescribing data allows pharmaceutical
companies to define physician profiles and adapt their information
strategies; measure the effectiveness of their information; and
perform general interest studies on the markets in which they are
present or that they wish to develop;
OneKey: A comprehensive international healthcare professional
database; and
Physician Connect. Offers an advanced solution for identifying
prescribers who influence peers' prescription writing behaviors.
Physician Connect evaluates the existing ties among key opinion
leaders and prescribers, and makes it possible to identify local
networks of influence among physicians treating a specific pathology
at the local, regional or national level, for therapeutic management
and continuing education purposes.
About Cegedim:
Founded in 1969, Cegedim is a global technology and services company
specializing in the healthcare field. Cegedim supplies services,
technological tools, specialized software, data flow management services
and databases. Its offerings are targeted notably at healthcare
industries, pharmaceutical companies, healthcare professionals and
insurance companies.
The world leader in pharmaceutical CRM, Cegedim is also one of the
leading suppliers of strategic healthcare industry data. Cegedim employs
more than 8,000 people in 80 countries and generated revenue of €753 million
in 2007. To learn more, please visit our website: www.cegedim.com
Listed on NYSE Euronext Paris, compartment B –
ISIN FR0000053506 – Reuters CGDM.PA –
Bloomberg CGM
About Skila
Skila is a global technology and services company specializing in
knowledge and effectiveness solutions for the healthcare industry. Skila’s
solutions address the broad needs of global marketing, medical,
executive and alliance management teams. These solutions include a
unique methodology, robust technology and key continuous services for
effectively managing global product launches, key opinion leader
relationships, business performance, competitive intelligence, and key
partnerships and alliances.
Having developed strong relationships with a broad number of global
Pharmaceutical companies, Skila’s solutions
have been deployed in 56 countries, supporting numerous global brands
and over 10 million user interactions. Skila’s
long-standing commitment and understanding of customers’
needs has resulted in the long-term growth and adoption of our
methodology, technology and continuous services as the business platform
of choice for many of our clients. To learn more about Skila visit our
website at www.skila.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Cegedim S.A.mehr Nachrichten
Keine Nachrichten verfügbar. |